Archived Insight | January 13, 2021

HHS Extends the National Public Health Emergency into April

The federal government has extended the COVID-19 public health emergency for an additional 90 days, until April 21, 2021.

This is the fourth extension of the emergency, which the secretary of the Department of Health and Human Services initially declared on January 31, 2020 (retroactive to January 27, 2020). The secretary could terminate the public health emergency earlier than April 21, 2021 or extend it again.

National Public Health Emergency extended into April

This public emergency declaration is important to health plan sponsors because it determines the period of time during which group health plans and insurers must pay for COVID-19 tests and related services without charging cost sharing. In addition, non-grandfathered plans must cover vaccines in network as a preventive benefit, but during the public emergency must also cover it on an out-of-network basis.

Have questions about how the emergency declarations affect your health plan?

We have answers.

Get in Touch

See more insights

Female Nutritionist Holding Image Of Healthy Eating Plate

Health Coaching Enhances Well-Being and Productivity

Your organization can derive significant value from integrating health coaching into its existing health-management programs.

Health, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Architecture Engineering & Construction, Pharmaceutical, Corporate

Read Full Insight

Lawyer And Business Person Discussing In The Office

Supreme Court Addresses Prohibited Transaction Lawsuits

As a result of the Supreme Court’s decision, it will be easier for participants to sue plans for everyday plan transactions with service providers.

Retirement, Compliance, Multiemployer Plans, Healthcare Industry, Higher Education, Architecture Engineering & Construction, Corporate

Read Full Insight

Pharmacist Taking Inventory With Digital Tablet

Executive Order Seeks to Lower Prescription Drug Prices

The order instructs federal departments to issue regulations or work with Congress to identify statutory changes necessary to address drug prices.

Health, Compliance, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Architecture Engineering & Construction, Pharmaceutical, Corporate

Read Full Insight

This page is for informational purposes only and does not constitute legal, tax or investment advice. You are encouraged to discuss the issues raised here with your legal, tax and other advisors before determining how the issues apply to your specific situations.